3 completed, 2 terminated, 2 unknown. 7 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Terminated 2, Unknown 2 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow advexin: new trials by email Literature Review of advexin trials Research Report on advexin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer Ad-P53, Xeloda, Keytruda - Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer | Phase 1 / Phase 2 | Terminated | MultiVir, Inc. | 4 | 2018-11-20 | 2020-06-02 |
| Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. Ad-p53 - Solid Tumor, Lymphoma | Phase 2 | Unknown | MultiVir, Inc. | 40 | 2018-10-01 | 2020-06-09 |
| Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx Ad5CMV-p53 gene, laboratory biomarker analysis - Lip and Oral Cavity Cancer, Oropharyngeal Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 51 | 2003-06-01 | 2013-01-23 |
| S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat Ad5CMV-p53 gene, cisplatin, conventional surgery - Head and Neck Cancer | Phase 2 | Terminated | SWOG Cancer Research Network | 13 | 2003-02-01 | 2012-06-14 |
| Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer Ad5CMV-p53 gene, docetaxel, doxorubicin hydrochloride - Breast Cancer | Phase 2 | Completed | Introgen Therapeutics | 2002-02-01 | 2013-05-30 | |
| Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer Ad5CMV-p53 gene - Head and Neck Cancer | Phase 2 | Unknown | Aventis Pharmaceuticals | 39 | 1998-01-01 | 2013-12-04 |
| Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer INGN 201 - Locally Advanced Breast Cancer (LABC) | Phase 2 | Completed | Introgen Therapeutics | 60 | 2008-04-01 |
Head and Neck Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (2) · Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Esophageal Neoplasms (1) · Hodgkin Disease (1) · Liver Neoplasms (1) · Lymphoma (1) · Melanoma (1) · Mouth Neoplasms (1)
Introgen Therapeutics (2) · MultiVir, Inc. (2) · Aventis Pharmaceuticals (1) · National Cancer Institute (NCI) (1) · SWOG Cancer Research Network (1)
United States (7)
Gary L. Clayman (1) · George H. Yoo, MD (1) · Jill Van Warthood, PhD (1) · Lyndah Dreiling, MD (1) · Vivek Subbiah, MD (1)
P50CA097007 (1), U10CA032102 (1)